Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 18/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882675 | 0.90 | CXCR4 (0.62) | CXCR4CYP3A4CHRM2CYP2D6DRD2 | |
| SCHEMBL14270192 | 0.89 | CXCR4 (0.52) | CXCR4CYP3A4CHRM2CYP2D6DRD2 | |
| SCHEMBL4887285 | 0.87 | CXCR4 (0.56) | CXCR4CYP3A4CHRM2CYP2D6DRD2 | |
| SCHEMBL4886852 | 0.87 | CXCR4 (0.56) | CXCR4CYP3A4CHRM2CYP2D6DRD2 | |
| SCHEMBL4880669 | 0.87 | CXCR4 (0.56) | CXCR4CYP3A4CHRM2CYP2D6DRD2 | |
| SCHEMBL4892180 | 0.86 | CXCR4 (0.58) | CXCR4CYP3A4CHRM2CYP2D6DRD2 | |
| SCHEMBL4886423 | 0.86 | CXCR4 (0.58) | CXCR4CYP3A4CHRM2CYP2D6DRD2 | |
| SCHEMBL4889547 | 0.86 | CXCR4 (0.58) | CXCR4CYP3A4CHRM2CYP2D6DRD2 | |
| SCHEMBL4881728 | 0.85 | CXCR4 (0.60) | CXCR4CYP3A4CHRM2CYP2D6DRD2 | |
| SCHEMBL4889403 | 0.85 | CXCR4 (0.60) | CXCR4CYP3A4CHRM2CYP2D6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045537-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-02-21 | — | — | US | claimed |
| EP-1789045-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-30 | — | — | EP | claimed |
| WO-2006023400-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-02 | — | — | WO | claimed |
| US-20080045537-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-02-21 | — | — | US | disclosed |
| EP-1789045-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006023400-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045537-A1 | Chemical Compounds | CCR5, CXCR4, CXCR3 | CXCR4 2/4885CYP3A4 3349/4885CHRM2 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.